Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06433947 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
A Phase 1 study of Refractory Multiple Myeloma and Relapsed Multiple Myeloma, sponsored by Opna Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
- 10
- Study locations
NCT06433947: Recruiting Phase 1 study of Refractory Multiple Myeloma and Relapsed Multiple Myeloma, sponsored by Opna Bio.
NCT06433947 is a Phase 1 study of Refractory Multiple Myeloma and Relapsed Multiple Myeloma that is actively recruiting participants, run by Opna Bio. The registered enrollment target is 130 participants, above the 46-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (183% higher). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06433947, a Phase 1 study of Refractory Multiple Myeloma and Relapsed Multiple Myeloma, is actively recruiting participants, sponsored by Opna Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
- 10
- Study locations
Study Summary
Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.
Conditions Studied
Interventions
- DRUG OPN-6602
- DRUG Dexamethasone
Study Locations (10)
Michigan
- Karmanos Cancer Institute - Detroit
- START Midwest - Grand Rapids
Arizona
- Banner MD Anderson - Gilbert
California
- Stanford Cancer Institute - Stanford
Georgia
- Emory Winchip Cancer Center - Atlanta
Kansas
- University of Kansas Clinical Research Center - Westwood
Massachusetts
- Dana Farber Cancer Institute - Boston
New York
- University of Rochester Medical Center - Rochester
Utah
- Huntsman Cancer Center Institute University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2024-08-22 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
What NCT06433947 shows while recruiting
NCT06433947 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, above the 46-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (183% higher).
The record links to 2 conditions, with Refractory Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which OPN-6602 is the first listed.
NCT06433947 lists 10 locations in 9 states (Michigan, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT06433947 about?
NCT06433947 is a clinical study titled "Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma". Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.
What is the current status of trial NCT06433947?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2024-08-22. Estimated completion is 2026-07.
What conditions does trial NCT06433947 study?
This clinical trial studies the following conditions: Refractory Multiple Myeloma, Relapsed Multiple Myeloma.
What interventions are being tested in trial NCT06433947?
The interventions under investigation include: OPN-6602 (DRUG), Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT06433947?
This trial is sponsored by Opna Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06433947 being conducted?
This trial has 10 study locations across Arizona, California, Georgia, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06433947's enrollment target sits among peer trials
130 3rd of 67 higher than 63 of 67 other Refractory Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
RECRUITING · Phase 1
-
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI